Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers

• Main Authors: Jacinthe Leclerc (Author), Claudia Blais (Author), Louis Rochette (Author), Denis Hamel (Author), Line Guénette (Author), Claudia Beaudoin (Author), Paul Poirier (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background It is unclear whether generics are as safe as brand-name drugs in cardiology. For public health surveillance purposes, we evaluated if switching from the brand-name losartan, valsartan, or candesartan impacted the occurrence of the following outcomes: emergency room (ER) consulta...